Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People
Bloomberg Businessweek - Un pódcast de Bloomberg
Categorías:
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF. Bloomberg News Health Care Reporter Madison Muller discusses that patients taking Eli Lilly’s blockbuster weight-loss shot were 94% less likely to develop diabetes in a three-year study that illuminates the long-term health benefits of treating obesity.Hosts: Tim Stenovec and Katie Greifeld. Producer: Paul Brennan. See omnystudio.com/listener for privacy information.
